Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 45-51

  Raiden, Silvina ^a   Nahmod, Karen ^b   Nahmod, Víctor ^a   Semeniuk, Guillermo ^b   Pereira, Yanina ^a   Alvarez, Clarisa ^a   Giordano, Mirta ^b   Geffner, Jorge R ^b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FORMYLMETHIONYLPHENYLALANINE; IRBESARTAN; LOSARTAN; SARALASIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LUNG CLEARANCE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RESPIRATORY DISTRESS SYNDROME;

ANGIOTENSIN II; ANIMALS; BORDETELLA BRONCHISEPTICA; BORDETELLA INFECTIONS; CALCIUM; KINETICS; LOSARTAN; LUNG; MALE; NEUTROPHILS; OXYGEN; PEROXIDASE; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0036784535     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037382     Document Type: Article

References (47)

1. Ardaillou R (1999) Angiotensin II receptors. J Am Soc Nephrol 10 (Suppl 11): S30-S39.
2. ARDS Network Authors (2000) Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. J Am Med Assoc 283:1995-2002.
3. Bernstein KE and Alexander RW (1992) Counterpoint: molecular analysis of the angiotensin II receptor. Endocr Rev 13:381-386.
4. Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, and John GW (1994) Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 268:747-752.
5. Broug-Holub E, Toews GB, van Iwaarden JF, Strieter RM, Kunkel SL, Paine R, and Standiford TJ (1997) Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 65:1139-1146.
6. Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Dawson DV, and Berger M (1999) IL-10 attenuates excesive inflammation in chronic Pseudomonas infection in mice. Am J Resp Crit Care Med 160:2040-2047.
7. Clauser E, Curnow KM, Davies E, Conchon S, Teutsch B, Vianello B, Monnot C, and Corvol P (1996) Angiotensin II receptors: protein and gene structures, expression and potential pathological involvement. Eur J Endocrinol 134:403-411.
8. Doring G and Dauner HM (1988) Clearance of Pseudomonas aeruginosa in different rat lung models. Am Rev Respir Dis 138:1249-1253.
9. 2+ and the involvement of cyclic GMP. Br J Pharmacol 121:643-648.
10. Feng YH, Noda K, Saad Y, Liu XP, Husain A, and Karnik SS (1995) The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem 270:12846-12850.
11. Fillion I, Ouellet N, Simard M, Bergeron Y, Sato S, and Bergeron MG (2001) Role of chemokines and formyl peptides in pneumococcal pneumonia-induced monocyte/macrophage recruitment. J Immunol 166:7353-7361.
12. Gattinoni L, Bombino M, and Pelosi P (1994) Lung structure and function in different stages of ARDS. J Am Med Assoc 271:1772-1779.
13. Goff CD, Corbin RS, Theiss SD, Frierson HF, Cephas GA, Tribble CG, Kron IL, and Young JS (1997) Postinjury thromboxane receptor blockade ameliorates acute lung injury. Ann Thorac Surg 64:826-829.
14. Hoe KL and Saavedra JM (2002) Site-directed mutagenesis of the gerbil and human angiotensin II AT(1) receptors identifies amino acid residues attributable to the binding affinity for the nonpeptidic antagonist losartan. Mol Pharmacol 61:1404-1415.
15. Hunyady L, Ji H, Jagadeesh G, Zhang M, Gaborik Z, Mihalik B, and Catt KJ (1998) Dependence of AT1 angiotensin receptor function on adjacent asparagines residues in the seventh transmembrane helix. Mol Pharmacol 54:427-434.
16. Johnston CI (1995) Angiotensin receptor antagonists: focus on losartan. Lancet 346:1403-1407.
17. Kao JPY, Harootunian AT, and Tsien RY (1989) Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem 264:8179-8184.
18. Kooguchi K, Hashimoto S, Kobayashi A, Kitamura Y, Kudoh I, Wiener-Kronish J, and Sawa T (1998) Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect Immun 66:3164-3169.
19. Kranzhofer R, Browatzki M, Schmidt J, and Kubler W (1999) Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem Biophys Res Commun 257:826-828.
20. Li P, Ferrario CM, and Brosnihan KB (1997) Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 281:1065-1070.
21. Li P, Ferrario CM, and Brosnihan KB (1998) Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 32:198-205.
22. Li P, Fukuhara M, Diz DI, Ferrario CM, and Brosnihan KB (2000) Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 292:238-246.
23. Lijnen P, Fagard R, and Petrov V (1997) Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype 1 receptors. J Hypertens 15:871-876.
24. Liu ECK, Hedberg A, Goldenberg HG, Harris DN, and Webb IM (1992) Dup 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 44:89-99.
25. Miettinen HM, Mills JS, Gripentrog JM, Dratz EA, Granger BL, and Jesaitis AJ (1997) The ligand binding site of the formyl peptide receptor maps in the transmembrane region. J Immunol 159:4045-4054.
26. Murphy PM (1994) The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12:593-633.
27. Nahmod VE, Dabsys SM, and Sterin-Princ AE (1992) Human monocytes produce angiotensin I and II and mediate the LPS stimulation of TNF-α release: effect of saralasin. 5th World Conference on Clinical Pharmacology and Therapeutics A0. 27.04.
28. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, and Karnik SS (1995) Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 270:2284-2289.
29. Perez HD, Holmes R, Vilander LR, Adams RR, Manzana W, Jolley D, and Andrews WH (1993) Formyl peptide receptor chimeras define domains involved in ligand binding. J Biol Chem 268:2292-2295.
30. Perez HD, Vilander L, Andrews WH, and Holmes R (1994) Human formyl peptide receptor ligand binding domain(s): studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of the receptor occupancy. J Biol Chem 269:22485-22487.
31. Quehenberger O, Prossnitz ER, Cavanagh SL, Cochrane CG, and Ye RD (1993) Multiple domains of the N-formyl peptide receptor are required for high affinity ligand binding. J Biol Chem 268:18167-18175.
32. Raiden S, Giordano M, Andonegui G, Trevani AS, López DH, Nahmod V, and Geffner JR (1997) Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Ther 281:624-628.
33. Raiden S, Pereyra Y, Nahmod V, Alvarez C, Castello L, Giordano M, and Geffner JR (2000) Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP. J Leukoc Biol 68:700-706.
34. Regoli D, Park WK, and Rioux F (1974) Pharmacology of angiotensin. Pharmacol Rev 26:69-123.
35. 4 integrin. Circ Res 81:196-201.
36. Shanley TP, Schmal H, Warner RL, Schmid E, Friedl HP, and Ward PA (1997) Requirements for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J Immunol 158:3439-3448.
37. SinuffT, Cook DJ, Peterson JC, and Fuller HD (1999) Development, implementation and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 14:1-6.
38. Slotman GJ, Burchard KW, D'Arezzo A, and Gann DS (1988) Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 28:648-654.
39. Thies SD, Corbin RS, Goff CD, Binns OA, Buchanan SA, Shockey KS, Frierson HF, Young JS, and Tribble CG (1996) Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. Ann Thorac Surg 61: 1453-1457.
40. Timmermans PB (1999) Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 22:147-153.
41. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye J, and Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.
42. Ware LB and Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342:1334-1349.
43. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, and Gadek JE (1986) Lung neutrophils in the adult respiratory syndrome. Clinical and pathophysiologic significance. Am Rev Respir Dis 133:218-225.
44. Wisner D, Sturm J, Sutter G, Ellendorf B, and Nerlich M (1988) Thromboxane receptor blockade in an animal model of ARDS. Surgery 104:91-97.
45. Wyncoll DL and Evans TW (1999) Acute respiratory distress syndrome. Lancet 354:497-501.
46. Yu M and Tomasa G (1993) A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 21:1635-1642.
47. Zhang P, Summer WR, Bagby GJ, and Nelson S (2000) Innate immunity and pulmonary host defense. Immunol Rev 173:39-51.